FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Spear Matthew A.						2. Issuer Name and Ticker or Trading Symbol Poseida Therapeutics, Inc. [PSTX]									all applicable) Director Officer (give title		g Person(s) to Issuer 10% Owner Other (specify		vner	
	EIDA THE	ERAPEUTICS, I				3. Date of Earliest Transaction (Month/Day/Year) 03/01/2022									Chief Medical Officer					
(Street) SAN DII	AN DIEGO CA 92121					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(5	-	(Zip)																	
		Tab	le I - Nor	ı-Deri\	/ative	e Se	curities	s Ac	quired,	Dis	posed c	of, or Be	enefici	ally	Owned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date,		Code	Transaction Disposed Of Code (Instr. 5)		ies Acquired (A) or Of (D) (Instr. 3, 4 and			5. Amou Securitie Benefici Owned F Reported	es ally Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) (D)	Pric	9	Transact (Instr. 3	tion(s)			(1113411 4)	
Common Stock 03/01/					1/202	/2022		A ⁽¹⁾	Г	50,00	000 A \$.00	111,485			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable Expiration Date (Month/Day/Year)			nd 7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		S	3. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amous or Number of Shares	er						
Employee Stock Option (Right to Buy)	\$3.42	03/01/2022			A		72,568		(2)	(02/29/2032	Common Stock	72,56	8	\$0.00	72,56	8	D		

Explanation of Responses:

- 1. Represents restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments.
- 2. 12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.

Remarks:

/s/ Harry J. Leonhardt, 03/01/2022 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.